Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Brief Summary: The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.


Options:
A: Arm Label: ABT-414/temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin, Drug: Temozolomide | Arm Label: ABT-414_adult; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Arm Label: Control_lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Arm Label: Control_ temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Arm Label: ABT-414_ pediatric; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): ABT-414/temozolomide, ABT-414_ pediatric, ABT-414_adult | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ABT-414/temozolomide, Control_ temozolomide | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): Control_lomustine
B: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control
C: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
D: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care

Answer: B